Literature DB >> 22352331

Allele and genotype frequencies of CYP2B6 and CYP2C19 polymorphisms in Egyptian agricultural workers.

Corie A Ellison1, Soheir S Abou El-Ella, Maha Tawfik, Pamela J Lein, James R Olson.   

Abstract

Genetic variability in cytochrome P-450 (CYP) has the potential to modify pharmacological and toxicological responses to many chemicals. Both CYP2B6 and CYP2C19 are pharmacologically and toxicologically relevant due to their ability to metabolize multiple drugs and environmental contaminants, including the organophosphorus (OP) pesticide chlorpyrifos. The aim of this study was to determine the prevalence of CYP2B6 and CYP2C19 variants in an indigenous Egyptian population (n = 120) that was shown to be occupationally exposed to chlorpyrifos. Further, the genotyping data was compared for Egyptians with previously studied populations to determine between population differences. Allelic frequencies were CYP2B6 1459C > T (3.8%), CYP2B6 785A > G (30.4%), CYP2B6 516G > T (28.8%), CYP2C19 681G > A (3.8%), and CYP2C19 431G > A (0%). The most prevalent CYP2B6 genotype combinations were CYP2B6 *1/*1 (44%), *1/*6 (38%), *6/*6 (8%), and *1/*5 (6%). The frequency of the CYP2C19 genotype combinations were CYP2C19 *1/*1 (93%), *1/*2 (6%), and *2/*2 (1%). The frequency of the CYP2B6 516G > T and CYP2B6 785A > G polymorphisms in this Egyptian cohort is similar to that found North American and European populations but significantly different from that reported for West African populations, while that of CYP2B6 1459C > T is similar to that found in Africans and African Americans. The observed frequency of CYP2C19 681G > A in Egyptians is similar to that of African pygmies but significantly different from other world populations, while CYP2C19 431 G > A was significantly different from that of African pygmies but similar to other world populations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22352331      PMCID: PMC3500531          DOI: 10.1080/15287394.2012.641201

Source DB:  PubMed          Journal:  J Toxicol Environ Health A        ISSN: 0098-4108


  48 in total

1.  Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.

Authors:  Miki Nakajima; Sayaka Komagata; Yuto Fujiki; Yoshihiro Kanada; Hiromichi Ebi; Kuniaki Itoh; Hirofumi Mukai; Tsuyoshi Yokoi; Hironobu Minami
Journal:  Pharmacogenet Genomics       Date:  2007-06       Impact factor: 2.089

2.  Genetic polymorphisms of cytochrome P450 2B6 gene in Han Chinese.

Authors:  Su Guan; Min Huang; Eli Chan; Xiao Chen; Wei Duan; Shu-Feng Zhou
Journal:  Eur J Pharm Sci       Date:  2006-05-02       Impact factor: 4.384

3.  Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.

Authors:  Hanjing Xie; Laimonas Griskevicius; Lars Ståhle; Zuzana Hassan; Umit Yasar; Anders Rane; Ulrika Broberg; Eva Kimby; Moustapha Hassan
Journal:  Eur J Pharm Sci       Date:  2005-09-23       Impact factor: 4.384

4.  Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea.

Authors:  Rajeev K Mehlotra; Mark N Ziats; Moses J Bockarie; Peter A Zimmerman
Journal:  Eur J Clin Pharmacol       Date:  2006-02-28       Impact factor: 2.953

5.  Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.

Authors:  Séverine Crettol; Jean-Jacques Déglon; Jacques Besson; Marina Croquette-Krokkar; Isabelle Gothuey; Robert Hämmig; Martine Monnat; Hardy Hüttemann; Pierre Baumann; Chin B Eap
Journal:  Clin Pharmacol Ther       Date:  2005-12       Impact factor: 6.875

6.  Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism.

Authors:  Aleksandra Galetin; J Brian Houston
Journal:  J Pharmacol Exp Ther       Date:  2006-06-08       Impact factor: 4.030

7.  Human hepatic cytochrome p450-specific metabolism of parathion and chlorpyrifos.

Authors:  Robert J Foxenberg; Barbara P McGarrigle; James B Knaak; Paul J Kostyniak; James R Olson
Journal:  Drug Metab Dispos       Date:  2006-11-01       Impact factor: 3.922

8.  Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.

Authors:  Zeruesenay Desta; Tanja Saussele; Bryan Ward; Julia Blievernicht; Lang Li; Kathrin Klein; David A Flockhart; Ulrich M Zanger
Journal:  Pharmacogenomics       Date:  2007-06       Impact factor: 2.533

9.  GST CYP and PON1 polymorphisms in farmers attributing ill health to organophosphate-containing sheep dip.

Authors:  A C Povey; F Jury; W M Dippnall; A E Smith; S Thomson; B Mackness; M Mackness; P Durrington; N M Cherry
Journal:  Biomarkers       Date:  2007 Mar-Apr       Impact factor: 2.658

10.  Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.

Authors:  Ulrich M Zanger; Kathrin Klein; Tanja Saussele; Julia Blievernicht; Marco H Hofmann; Matthias Schwab
Journal:  Pharmacogenomics       Date:  2007-07       Impact factor: 2.533

View more
  9 in total

Review 1.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

2.  Allele and genotype frequencies of CYP2B6 in a Turkish population.

Authors:  Nazan Yuce-Artun; Gulcin Kose; H Sinan Suzen
Journal:  Mol Biol Rep       Date:  2014-02-22       Impact factor: 2.316

3.  Distribution of alleles, genotypes and haplotypes of the CYP2B6 (rs3745274; rs2279343) and CYP3A4 (rs2740574) genes in the Malian population: Implication for pharmacogenetics.

Authors:  Yaya Kassogue; Brehima Diakite; Oumar Kassogue; Issa Konate; Kadidiatou Tamboura; Zoumana Diarra; Mamoudou Maiga; Hind Dehbi; Sellama Nadifi; Cheick Bougadari Traore; Bakarou Kamate; Sounkalo Dao; Seydou Doumbia; Guimogo Dolo
Journal:  Medicine (Baltimore)       Date:  2021-07-23       Impact factor: 1.817

4.  The Role of CYP2B6*6 Gene Polymorphisms in 3,5,6-Trichloro-2-pyridinol Levels as a Biomarker of Chlorpyrifos Toxicity Among Indonesian Farmers.

Authors:  Jen Fuk Liem; Dwi A Suryandari; Safarina G Malik; Muchtaruddin Mansyur; Dewi S Soemarko; Aria Kekalih; Imam Subekti; Franciscus D Suyatna; Bertha Pangaribuan
Journal:  J Prev Med Public Health       Date:  2022-05-16

Review 5.  Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region.

Authors:  Renée Dagenais; Kyle John Wilby; Hazem Elewa; Mary H H Ensom
Journal:  Drugs R D       Date:  2017-09

6.  The Prevalence of CYP2B6 Gene Polymorphisms in Malaria-endemic Population of Timor in East Nusa Tenggara Indonesia.

Authors:  Linawati Hananta; Indwiani Astuti; Ahmad Hamim Sadewa; Josephine Alice; Jontari Hutagalung
Journal:  Osong Public Health Res Perspect       Date:  2018-08

Review 7.  Genetic polymorphisms as determinants of pesticide toxicity: Recent advances.

Authors:  Michele Teodoro; Giusi Briguglio; Concettina Fenga; Chiara Costa
Journal:  Toxicol Rep       Date:  2019-06-07

8.  Inconsistency in race and ethnic classification in pharmacogenetics studies and its potential clinical implications.

Authors:  Frederick Zhang; Joseph Finkelstein
Journal:  Pharmgenomics Pers Med       Date:  2019-07-02

9.  Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance.

Authors:  Ulrich M Zanger; Kathrin Klein
Journal:  Front Genet       Date:  2013-03-05       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.